

U.S.S.N. 09/706,045

Filed: November 3, 2000

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

**Amendment**

**In the Specification**

Please replace ~~the~~ the paragraph on page 23, lines 7-10 with the following amended paragraph:

*C1*  
Examples 15-17 describe experiments demonstrating the increased internal total surface area of porous drug matrices produced with pore forming agents. Examples 18-21 describe experiments demonstrating the advantage or need to include a wetting agent as a component of the porous drug matrices.

Please replace ~~the~~ the heading at page 32, lines 20-23 with the following amended heading:

*C2*  
**Example 17: Internal Total Surface Area of Porous Drug Matrices Containing a Wetting Agent and Produced With and Without a Pore**

**Forming Agent**

Please replace ~~the~~ the paragraph at page 32, lines 23-26 with the following amended paragraph:

*C3*  
The internal total surface areas of the drug matrices produced in Examples 15 and 16 were assessed by Krypton BET. BET specific surface area analysis was performed using multi-point surface area analysis with krypton as the gas. Samples were outgassed to 20 micron vacuum at 20 °C prior to analysis.

Please replace ~~the~~ the paragraph at page 32, lines 27-29 with the following amended paragraph:

U.S.S.N. 09/706,045

Filed: November 3, 2000

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

*C4*  
The results, shown in Table 4, illustrate that the use of the pore forming agent led to an increase of between 2.3 and 3.5 fold in the internal total surface area of the resultant drug matrix.

Please replace the heading at page 33, line 1 with the following amended heading:

*C5*  
**Table 4: Internal Total Surface Area of Drug Matrices**